公开(公告)号：US20160024483A1

公开(公告)日：2016-01-28

申请号：US14740194

申请日：2015-06-15

Applicant: Korea Advanced Institute of Science and Technology (KAIST) ,  Seoul National University Bundang Hospital

Inventor： Ho Min KIM ,  Hye Kyoung Hong ,  Se Joon Woo ,  Eun-Jin Lim ,  Kyu Hyung Park

IPC: C12N9/12 ,  C07K16/00

CPC classification number: C12N9/12 ,  A61K33/24 ,  A61K38/00 ,  A61K38/45 ,  A61K39/395 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/00 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/70 ,  C07K2319/91 ,  C12Y207/10001

Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and placenta growth factor (PIGF) polypeptide comprising a nucleotide sequence encoding a VEGFR1 component.

Abstract translation: 本申请描述了编码能够同时结合VEGF多肽和胎盘生长因子（PIGF）多肽的分离的核酸分子，其包含编码VEGFR1组分的核苷酸序列。

公开(公告)号：US20200148757A1

公开(公告)日：2020-05-14

申请号：US16625707

申请日：2018-07-02

Applicant: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ho Min KIM ,  Dae Hee LEE ,  Duk Ki KIM

IPC: C07K16/22 ,  A61K47/64 ,  C07K16/28 ,  C07K14/475

Abstract: The present invention relates to a VEGF-Grab protein-drug conjugate and a use thereof and, more particularly, to a conjugate of a fusion protein in which a VEGFR1 domain 2, a VEGFR1 domain 3, and an antibody fragment are connected and a drug, a pharmaceutical composition for prevention or treatment of cancer or angiogenesis-related disease, comprising the conjugate, and a method for prevention or treatment of cancer or angiogenesis-related disease. Serving as a multi-paratopic VEGF decoy receptor, the conjugate including a VEGF-Grab protein and a drug of the present invention can be used as a multi-purpose platform for treatment of cancer or angiogenesis-related disease.

公开(公告)号：US20240083959A1

公开(公告)日：2024-03-14

申请号：US18273080

申请日：2022-01-24

Applicant: INSTITUTE FOR BASIC SCIENCE ,  INHA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ho Min KIM ,  Do-Kyun KIM ,  Ji-Kan RYU

IPC: C07K14/47

CPC classification number: C07K14/473 ,  A61K38/00

Abstract: The present invention relates to a deglycosylated LRG1 glycoprotein and a LRG1 glycoprotein variant, and a use thereof. The deglycosylated LRG1 glycoprotein and LRG1 glycoprotein variant of the present invention exhibit effects of angiogenesis, nerve growth and nerve regeneration that are superior to those of conventional LRG1 glycoproteins, and thus a composition containing thereof is effective in preventing and treating vascular erectile dysfunction, ischemic heart/brain/peripheral vascular diseases, diabetic vascular complications, neurogenic erectile dysfunction, diabetic neurologic complications, post-operative/post-traumatic peripheral nerve damage, ischemic diseases including neurodegenerative diseases, peripheral nerve diseases, erectile dysfunction and/or neurodegenerative diseases.

公开(公告)号：US20160032259A1

公开(公告)日：2016-02-04

申请号：US14740158

申请日：2015-06-15

Applicant: Korea Advanced Institute of Science and Technology (KAIST)

Inventor： Ho Min KIM ,  Jung-Eun Lee ,  Chan Kim ,  Gou Young Koh ,  Gyun Min Lee

IPC: C12N9/12 ,  A61K38/45 ,  A61K39/395 ,  A61K33/24 ,  C07K16/00

CPC classification number: C12N9/12 ,  A61K33/24 ,  A61K38/00 ,  A61K38/45 ,  A61K39/395 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/00 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/70 ,  C07K2319/91 ,  C12Y207/10001

Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and placenta growth factor (PIGF) polypeptide comprising a nucleotide sequence encoding a VEGFR1 component.

Abstract translation: 本申请描述了编码能够同时结合VEGF多肽和胎盘生长因子（PIGF）多肽的分离的核酸分子，其包含编码VEGFR1组分的核苷酸序列。

公开(公告)号：US20240254240A1

公开(公告)日：2024-08-01

申请号：US18289602

申请日：2022-05-04

Applicant: INSTITUTE FOR BASIC SCIENCE ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ho Min KIM ,  Gou Young KOH ,  Gyunghee JO ,  Jiomil BAE

IPC: C07K16/28

CPC classification number: C07K16/2863 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/75 ,  C07K2317/92

Abstract: The present invention relates to a Tie2 agonistic antibody that binds to an Ig3 Fn3 domain of human Tie2 or an antigen-binding fragment thereof, wherein by binding of the antibody, homodimer Tie2 can form a polygonal assembly so as to be clustered and activated.

公开(公告)号：US20230070752A1

公开(公告)日：2023-03-09

申请号：US17273637

申请日：2020-08-19

Applicant: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ho Min KIM ,  Jae-Hee CHUNG ,  Eui-Cheol SHIN ,  Seon-Hui HONG

IPC: C07K14/555 ,  A61P3/10 ,  A61P31/12 ,  A61P35/00 ,  A61K38/00

Abstract: Disclosed are a novel interferon lambda variant produced through structure-based glycoengineering and a method of producing the same. The novel interferon lambda variant and the method of producing the same exhibit remarkably improved production and yield in mammalian cell lines using structural information-based glycoengineering even through conventional purification protocols, and exhibit significantly improved therapeutic properties such as stability, half-life, and fraction of functional proteins during treatment, compared to wild-type interferon lambda. In addition, the novel interferon lambda variant and the method of producing the same according to the present invention have higher antiviral activity and interferon-stimulated gene (ISG)-inducing activity than wild-type interferon lambda, and thus are useful for the prevention and treatment of immune-related diseases such as cancer and autoimmune diseases as well as various viral infections such as infection with SARS-CoV-2 (COVID-19).